PMID- 35961637 OWN - NLM STAT- MEDLINE DCOM- 20221012 LR - 20221013 IS - 1536-0229 (Electronic) IS - 0363-9762 (Linking) VI - 47 IP - 11 DP - 2022 Nov 1 TI - Baseline 18 F-FDG PET/CT May Portend the Prognosis of Patients With Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma After First-Line Treatment. PG - 954-960 LID - 10.1097/RLU.0000000000004362 [doi] AB - PURPOSE: The outcome of patients with Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL) is variable. We aim to study if baseline 18 F-FDG PET/CT has some prognostic significance in WM/LPL. METHODS: Thirty-three patients with newly diagnosed WM/LPL who underwent baseline 18 F-FDG PET/CT and received active treatment thereafter were recruited in this retrospective study. Semiquantitative indices of baseline 18 F-FDG PET/CT were measured as total lesion glycolysis (TLG), metabolic tumor volume (MTV), and SUV max . The patients were followed up for at least 3 years or until reaching the endpoint, which were defined as progression-free survival (PFS) and the time to next treatment (TTNT). RESULTS: The overall response rate of the first-line treatment in the recruited patients was 84.8% (28/33). The 3-year PFS and overall survival rates were 56.3% and 89.3%, respectively. Patients with PFS <36 months and TTNT <36 months showed TLG and MTV significantly higher than those with PFS >/=36 months and TTNT >/=36 months ( P < 0.05). SUV max in patients with PFS <36 months was significantly higher than those with PFS >/=36 months ( P = 0.033). Receiver operating characteristic analysis demonstrated that cutoff values of TLG >291.28 SUVbw * mL, MTV >108.78 mL, and SUV max >3.16 were optimal for predicting PFS <36 months. Kaplan-Meier analysis showed that TLG >291.28 SUVbw * mL and MTV >108.78 mL were predictive for shorter PFS ( P = 0.003) and TTNT ( P = 0.002). In multivariate analysis, TLG >291.28 SUVbw * mL and MTV >108.78 mL were independent predictors for shorter PFS (hazard ratio, 3.06; 95% confidence interval, 1.09-8.57; P = 0.033) and TTNT (hazard ratio, 10.01; 95% confidence interval, 2.56-39.22; P = 0.001). CONCLUSIONS: The metabolic indices of TLG and MTV in baseline 18 F-FDG PET/CT were independent prognostic factors to predict PFS and TTNT in patients with WM/LPL. CI - Copyright (c) 2022 Wolters Kluwer Health, Inc. All rights reserved. FAU - Pan, Qingqing AU - Pan Q FAU - Cao, Xinxin AU - Cao X AD - Department of Hematology, Chinese Academy of Medical Sciences and Peking Union Medical College Hospital, Beijing, People's Republic of China. FAU - Luo, Yaping AU - Luo Y FAU - Li, Jian AU - Li J AD - Department of Hematology, Chinese Academy of Medical Sciences and Peking Union Medical College Hospital, Beijing, People's Republic of China. FAU - Li, Fang AU - Li F LA - eng PT - Journal Article DEP - 20220816 PL - United States TA - Clin Nucl Med JT - Clinical nuclear medicine JID - 7611109 RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18) SB - IM MH - Fluorodeoxyglucose F18/metabolism MH - Glycolysis MH - Humans MH - *Lymphoma MH - Positron Emission Tomography Computed Tomography MH - Prognosis MH - Retrospective Studies MH - Tumor Burden MH - *Waldenstrom Macroglobulinemia/diagnostic imaging COIS- Conflicts of interest and sources of funding: The authors declare that they have no conflicts of interest. This work is supported by the National Natural Science Foundation of China (81701741), CAMS Initiative for Innovative Medicine (CAMS-I2M, 2017-I2M-3-001), and the Beijing Natural Science Foundation (7202160). EDAT- 2022/08/13 06:00 MHDA- 2022/10/13 06:00 CRDT- 2022/08/12 19:42 PHST- 2022/08/13 06:00 [pubmed] PHST- 2022/10/13 06:00 [medline] PHST- 2022/08/12 19:42 [entrez] AID - 00003072-202211000-00006 [pii] AID - 10.1097/RLU.0000000000004362 [doi] PST - ppublish SO - Clin Nucl Med. 2022 Nov 1;47(11):954-960. doi: 10.1097/RLU.0000000000004362. Epub 2022 Aug 16.